Bal Pharma Limited (NSE:BALPHARMA)

Bal Pharma Statistics

Total Valuation

Bal Pharma has a market cap or net worth of INR 1.15 billion. The enterprise value is 2.60 billion.

Market Cap	1.15B
Enterprise Value	2.60B

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Sep 18, 2025

Share Statistics

Current Share Class	15.92M
Shares Outstanding	n/a
Shares Change (YoY)	-1.61%
Shares Change (QoQ)	+2.18%
Owned by Insiders (%)	52.16%
Owned by Institutions (%)	n/a
Float	5.47M

Valuation Ratios

The trailing PE ratio is 16.80.

PE Ratio	16.80
Forward PE	n/a
PS Ratio	0.39
PB Ratio	1.46
P/TBV Ratio	1.85
P/FCF Ratio	23.53
P/OCF Ratio	5.98
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.52, with an EV/FCF ratio of 53.45.

EV / Earnings	38.16
EV / Sales	0.88
EV / EBITDA	10.52
EV / EBIT	14.66
EV / FCF	53.45

Financial Position

The company has a current ratio of 1.07, with a Debt / Equity ratio of 1.98.

Current Ratio	1.07
Quick Ratio	0.44
Debt / Equity	1.98
Debt / EBITDA	6.26
Debt / FCF	31.79
Interest Coverage	1.22

Financial Efficiency

Return on equity (ROE) is 9.33% and return on invested capital (ROIC) is 4.84%.

Return on Equity (ROE)	9.33%
Return on Assets (ROA)	3.22%
Return on Invested Capital (ROIC)	4.84%
Return on Capital Employed (ROCE)	14.75%
Revenue Per Employee	2.99M
Profits Per Employee	69,214
Employee Count	986
Asset Turnover	0.86
Inventory Turnover	1.58

Taxes

Income Tax	-27.77M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -41.55% in the last 52 weeks. The beta is 0.20, so Bal Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.20
52-Week Price Change	-41.55%
50-Day Moving Average	77.55
200-Day Moving Average	90.64
Relative Strength Index (RSI)	38.00
Average Volume (20 Days)	7,244

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bal Pharma had revenue of INR 2.95 billion and earned 68.25 million in profits. Earnings per share was 4.29.

Revenue	2.95B
Gross Profit	1.35B
Operating Income	177.65M
Pretax Income	40.85M
Net Income	68.25M
EBITDA	234.06M
EBIT	177.65M
Earnings Per Share (EPS)	4.29

Balance Sheet

The company has 91.26 million in cash and 1.55 billion in debt, giving a net cash position of -1.46 billion.

Cash & Cash Equivalents	91.26M
Total Debt	1.55B
Net Cash	-1.46B
Net Cash Per Share	n/a
Equity (Book Value)	783.30M
Book Value Per Share	49.68
Working Capital	161.13M

Cash Flow

In the last 12 months, operating cash flow was 191.63 million and capital expenditures -142.91 million, giving a free cash flow of 48.73 million.

Operating Cash Flow	191.63M
Capital Expenditures	-142.91M
Free Cash Flow	48.73M
FCF Per Share	n/a

Margins

Gross margin is 45.89%, with operating and profit margins of 6.02% and 2.31%.

Gross Margin	45.89%
Operating Margin	6.02%
Pretax Margin	1.39%
Profit Margin	2.31%
EBITDA Margin	7.94%
EBIT Margin	6.02%
FCF Margin	1.65%

Dividends & Yields

This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.62%.

Dividend Per Share	1.20
Dividend Yield	1.62%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	1.61%
Shareholder Yield	3.23%
Earnings Yield	5.95%
FCF Yield	4.25%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	6